医学
肾脏疾病
背景(考古学)
立场声明
重症监护医学
立场文件
临床实习
指南
疾病
疾病管理
最佳实践
家庭医学
内科学
病理
管理
经济
古生物学
帕金森病
生物
作者
Francesco Locatelli,Peter Bárány,Adrian Covic,Angel de Francisco,Lucia Del Vecchio,David Goldsmith,Walter H. Hörl,Gérard M. London,Raymond Vanholder,Wim Van Biesen,Daniel Abramovicz,Jorge B. Cannata‐Andía,Pierre Cochat,Kai‐Uwe Eckardt,Denis Fouque,Olof Heimbürger,Kitty J. Jager,S. Jenkins,Elizabeth Lindley,Alison M. MacLeod
摘要
Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) group has produced comprehensive clinical practice guidelines for the management of anaemia in CKD patients. These guidelines addressed all of the important points related to anaemia management in CKD patients, including therapy with erythropoieis stimulating agents (ESA), iron therapy, ESA resistance and blood transfusion use. Because most guidelines were ‘soft’ rather than ‘strong’, and because global guidelines need to be adapted and implemented into the regional context where they are used, on behalf of the European Renal Best Practice Advisory Board some of its members, and other external experts in this field, who were not participants in the KDIGO guidelines group, were invited to participate in this anaemia working group to examine and comment on the KDIGO documents in this position paper. In this article, the group concentrated only on those guidelines which we considered worth amending or adapting. All guidelines not specifically mentioned are fully endorsed.
科研通智能强力驱动
Strongly Powered by AbleSci AI